Figure 9.

A) In vitro cytotoxicity and apoptosis of cells treated with cisplatin, CP5 NPs, or cisplatin + control NPs. Reproduced with permission.^{[ 128 ]} Copyright 2018, American Chemical Society. B) Histogram of particle‐size distribution of P6 NPs obtained by DLS and TEM morphologies of P6 NPs stored in water. Reproduced with permission.^{[ 129 ]} Copyright 2019, American Chemical Society. C) Diagram showing the Preparation Process and Mechanisms Underlying the Effects of X‐PDT with LiLuF4:Ce@SiO₂@Ag₃PO₄@Pt(IV) NPs. Reproduced with permission.^{[ 133 ]} Copyright 2018, American Chemical Society. D) In vivo bioluminescence images of mice bearing luciferase PC3 cell xenograft tumors post 10 d treatment with different groups. And resected luciferase‐expressing PC3 tumors from experimental groups at the 21st day. Reproduced with permission.^{[ 134 ]} Copyright 2017, Wiley‐VCH. E) Schematic illustration of the preparation of amphiphilic PCCO prodrug. Reproduced with permission.^{[ 135 ]} Copyright 2018, Elsevier. F) Schematic illustration of TrxR‐responsive DDS for ROS‐mediated chemosensitization and anti‐recurrence/metastasis therapy based on TrxR activity inhibition. Reproduced with permission.^{[ 144 ]} Copyright 2020, Elsevier. G) H&E staining images for major organs of MCF‐7 tumor‐bearing nude mice after different treatments for 15 days. Reproduced with permission.^{[ 149 ]} Copyright 2019, American Chemical Society. H) ROS responsive polymer‐drug conjugates in vitro In vivo antitumor efficacy and body weigh after intravenous injection of different drug formulations (with POD‐equivalent dose of 2.5, 5, and 10 mg kg⁻¹, respectively). Reproduced with permission.^{[ 150 ]} Copyright 2019, Royal Society of Chemistry. I) Self‐assembly of MPP NPs and the ROS generation process. Reproduced with permission.^{[ 155 ]} Copyright 2020, Elsevier.